Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ABVC Biopharma Inc
ABVC
Healthcare
Biotechnology
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504...
, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:ABVC)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
Next
(10)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 12:24pm
ABVC BioPharma, Inc. (NASDAQ: ABVC): A Promising Biopharmace
https://beyondspx.com/2024/07/31/abvc-biopharma-inc-nasdaq-abvc-a-promising-biopharmaceutical-player-navigating-the-ophthalmology-cns-and-oncology-hematology-landscapes/
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 26, 2024 10:03am
ABVC.....Let the bleeding continue
Sheesh
(105)
•••
Iseneschal
X
Comment by
Iseneschal
on Mar 26, 2024 9:05am
RE:ABVC.....Early a.m runner on NR
Reading what a few are saying about ABVC ....... every PR this company puts out is a deal with some company you can’t do any DD on
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 26, 2024 9:00am
ABVC.....Early a.m runner on NR
Volume & Price action No position.... $1.60
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 21, 2023 8:30am
New Press Release - ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
FREMONT, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- viaNewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a U.S. patent...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 16, 2023 10:05am
New Press Release - ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M
FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Nov 15, 2023 9:00am
New Press Release - ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and...
read article.
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 27, 2023 10:35am
ABVC... slow death
JMHO The NR talked of Big #'s.......Talk is cheap It's all B ............ S
(105)
•••
Iseneschal
X
Comment by
Iseneschal
on Oct 27, 2023 10:19am
RE:RE:RE:ABVC.... All Chasers were laid out by the ST Whores
Well well well....Mr. Nib...the man with few words....always around a "train wreck" Explain yourself please....in English ; )
(59)
•••
Nibinator
X
Comment by
Nibinator
on Oct 27, 2023 3:24am
RE:RE:ABVC.... All Chasers were laid out by the ST Whores
Jump in at 2.88
(59)
•••
Nibinator
X
Comment by
Nibinator
on Oct 27, 2023 3:24am
RE:RE:ABVC.... All Chasers were laid out by the ST Whores
Jump in at 2.88
(59)
•••
Nibinator
X
Comment by
Nibinator
on Oct 27, 2023 3:22am
RE:ABVC.... All Chasers were laid out by the ST Whores
Yeah you did
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 26, 2023 3:34pm
ABVC...just don't get your hopes up
This will not end well
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 26, 2023 3:17pm
ABVC.... All Chasers were laid out by the ST Whores
Told ya !!!!!!
(105)
•••
Iseneschal
X
Post by
Iseneschal
on Oct 26, 2023 11:15am
ABVC....Here's what the ST Pumpers are saying:
Huge upside potential here $667 mil deal with 9 mil market cap
Prev
1
2
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Largest integrated facility services provider in Canada releases financial results for Q1, 2025
Healthcare and Clinical Stage Drug Development Company Acquires NoBrainer Imaging Centers
This company is set to benefit from a change in Ontario legislation
How Web3 Will Fundamentally Reshape Finance